A case of antiphospholipid syndrome associated with hemorrhagic diathesis

Hemorrhagic diathesis rarely appeares in Antiphospholipid Syndrome, and was explained by the observed significant low levels of Factor II and Factor IX in the present case.

📌 3 Key Takeaways

🎯

Objective & Hypothesis:Herein, we report a 22 year-old female patient who had complaints of petechiae at the lower extremity, ecchymoses, hematuria and menorrhagia and history of premature birth in the 32nd week of her pregnancy.

📊

Key Findings & Data:Initial tests revealed that Prothrombin Time, International Normalized Ratio and Activated Partial Thromboplastin Time were 19-85s (N: 12-16), 1.92 (N: 0.95-1.5) and 73.5s (N: 26-46), respectively.

💡

Conclusion & Impact:Hemorrhagic diathesis rarely appeares in Antiphospholipid Syndrome, and was explained by the observed significant low levels of Factor II and Factor IX in the present case.

🔬Design:Research Article

📍Scope:Comprehensive Sample

⚙️Variables:Domain Parameters

Abstract

Herein, we report a 22 year-old female patient who had complaints of petechiae at the lower extremity, ecchymoses, hematuria and menorrhagia and history of premature birth in the 32nd week of her pregnancy. Initial tests revealed that Prothrombin Time, International Normalized Ratio and Activated Partial Thromboplastin Time were 19-85s (N: 12-16), 1.92 (N: 0.95-1.5) and 73.5s (N: 26-46), respectively. Factor II 35.4% (N:70-120), Factor V 67% (N:70-140), Factor VII 61% (N:170-140), Factor IX 33.51% (N:70-120), and Factor X 62% (N:70-120) were detected. Anticardiolipin antibody IgG was 60U/ml, Ig M was 40U/ml and positive lupus anticoagulant levels were detected. In order to confirm the presence of lupus anticoagulant antibodies, the coagulation tests were repeated after adding phospholipids into the test environment. It was observed that the prolonged tests were improved. Hemorrhagic diathesis rarely appeares in Antiphospholipid Syndrome, and was explained by the observed significant low levels of Factor II and Factor IX in the present case.

Özet

Yirmi iki yaşında alt ekstremitede peteşi, ekimoz, hematüri ve menoraji yakınmaları ile başvuran kadın hastanın gebeliğinin 32. haftasında prematür doğum hikayesi vardı. Protrombin Zamanı: 19.8 sn (N: 12-16), International Normalized Ratio: 1.92 (N: 0,95-1,5) ve aktive Parsiyel Tromboplastin Zamanı: 73.5 sn (N: 26-40) tespit edildi. Faktör II: % 35.4 (N:70-120), Faktör V: % 67 (N:70-140), Faktör VII: % 61 (N:70-140), Faktör IX: % 33.51 (N:70-120), Faktör X: % 62 (N:70-120) olarak rapor edildi. Antikardiolipin antikor IgG: 60 Ü/ ml, IgM: 40 U/ml ve lupus antikoagülan pozitif bulundu. Lupus antikoagülan antikorlarının varlığını doğrulamak için koagülasyon testleri ortama fosfolipid eklenmesinden sonra tekrarlandı ve uzamış olan testlerin düzeldiği görüldü. AFS’nda çok nadir görülen kanama diyatezi, olgumuzda Faktör II ve IX aktivite düzeylerinde izlenen belirgin düşüklük ile açıklanmıştır.

🔖

Cite This Article

ALTUNTAŞ, F., EKİCİ, E., ESER, B., ÜNAL, A., CANÖZ, Ö., SİPAHİOĞLU, M. (2022). A case of antiphospholipid syndrome associated with hemorrhagic diathesis. Erciyes Tıp Dergisi, Cilt: 26 - Sayı: 3, 141–144. https://ajindex.com/articles/502835

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (16)

Guidelines. Guidelines on the investigation and management of the antiphospholipid syndrome. Br J Haematol 2000: 109; 704-715
Hughes GRV, Harris EN and Gharavi AE. The anticardiolipin syndrome. J Rheumatol 1986; 13: 4876-4879
Radhakrishnan J, Nickolas TL, Isom R. Nephrological and obstetric complications of the antiphospholipid syndrome. Expert Opin İnvestig Drugs 2002; 11: 819-829
Levine JS, Branch DW, Rauch J. The Antiphospholipid syndrome. N Engl J Med 2002; 34: 752-63
Bick RL, Arun B, Frenkel EP. Antiphospholipid thrombosis syndrome. Lectures. Ed: Orhan Ulutin. 15th international congress on thrombosis, October 16-21, 1998, Antalya, Türkiye, pp 155-162
Petri M. Epidemiology of the antiphospholipid antibody syndrome. J Autoimmun 2000; 15: 145-151
Merkel PA, Chang YC, Pierangeli SS, Convery K, Harris EN, Polisson RP. The prevalence and clinical associations of anticardiolipin antibodies in a large inception cohort of patients with connective tissue diseases. Am J Med 1996; 101: 576-583
Cervera R, Khamashta MA, Font J, et at. Systemic lupus erythematosus: Clinical and immunologic patterns of disease expression in a cohort of 1,000 patients Medicine 1993; 72: 13-24
Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus and in non-SLE disorders: prevalence and clinical significance. Ann intern Med 1990; 112: 682-698
Hughson MD, McCarty GA, Brumback RA. Spectrum of vascular pathology affecting patients with the antiphospholipid syndrome. Hum Pathol 1995; 26: 716– 724
Asherson RA. Antiphospholipid antibodies and syndromes. In: Lahita RG, ed. Systemic lupus erythematosus. 2nd ed. New York: Churchill Livingstone, 1992: 587-635
Nochy D, Daugas E, Droz D, et al. The intrarenal vascular lesions associated with primary antiphospholipid syndrome. J Am Soc Nephrol 1999; 10:507-5I8
Lockshin MD, Druzin ML, Goie S, et al. Antibody to cardiolipin as a predictor of fetal distress or death in pregnant patients with systemic lupus erythematosus. N Engl J Med 1985; 313:152-156
Oshiro BT, Silver RM, Scott JR, Yu H, Branch DW. Antiphospholipid antibodies and fetal death. Obstet Gynecol 1996; 87:489-493
Chong BH, Brighton TC and Chesterman CN. Antiphospholipid antibodies and platelets. Semin Thromb Hemost 1995; 21: 76
Cuadrado MJ, Mujic F, Munoz E, Khamashta MA, Hughes GRV. Thrombocytopenia in the antiphospholipid syndrome. Ann Rheum Dis 1